Mentioned in ?
References in periodicals archive ?
M2 EQUITYBITES-December 1, 2017-NHS Wales to fund Pfizer's Somavert
M2 PHARMA-December 1, 2017-NHS Wales to fund Pfizer's Somavert
No se ha demostrado asociacion de este tipo de lesiones con el tratamiento, especificamente de la cabergolina (10), aunque menos utilizada luego del advenimiento de los analogos de somatostatina (11), los pacientes recibieron en este caso octreotide, lanreotide y somavert.
FDA--Approved Pegylated Therapeutics Commercial Name Drug Name Native Compound PegIntron Peginterferon Interferon alpha-2b alpha-2b Pegasys Peginterferon Interferon alpha-2a alfa-2a Adagen Pegadamase Adenosine deaminase Oncaspar Pegaspargase Asparaginase Krystexxa Pegloticase Mammalian urate oxidase Neulasta Pegfilgrastim Granulocyte colony-stimulating factor Cimzia Certolizumab Therapeutic pegol monoclonal antibody Mircera Polyethylene Epoetin beta glycol-epoetin beta Somavert Pegvisomant Growth hormone receptor antagonist Half- Half- life of life of Native Pegylated Commercial Clinical Compound Compound Name Indication (hours) (hours) PegIntron Hepatitis C, gliomas 9 28 Pegasys Hepatitis C 8 65 Adagen Severe combined 0.
Others may be less well-known but equally valuable: Remicade, a therapy for rheumatoid arthritis (NYU), Gardasil, the cervical cancer vaccine (multiple inventors), Somavert, for the treatment of acromegaly (Ohio University), Vorinostat, for T-cell lymphoma, Latanoprost, for glaucoma, and Palivizumab, for respiratory syncytial virus (all Columbia University).
Prior to 2010, Pfizer Health AB produced its legacy products Genotropin [R] and Somavert [R] in separate facilities.
Treatment with Somavert normalized IGF-I levels in up to 92% of patients treated for a mean of 1 year in one study, and up to 82% of patients in a 12-week study.
Treatment with Somavert normalized IGF-I levels in up to 92% of patients treated for a mean of 1 year in one study, and up to 82% of patients in a 12-week study Compared with those on placebo, treatment was associated with improvements in signs and symptoms of the condition, such as ring size, soft tissue swelling, arthralgia, headache, perspiration, and fatigue.
SOMAVERT is marketed today by Pfizer in both the United States and Europe.
That market is currently dominated by once-a-month Sandostatin LAR(R) Depot (octreotide acetate for injectable suspension) from Novartis (NYSE: NVS) and includes daily injections of Somavert (pegvisomant for injection), a growth hormone receptor antagonist, from Pfizer (NYSE: PFE).
Somavert is a new therapeutic recombinant protein for treating certain growth hormone disorders in patients who respond inadequately to other treatments.